A role for the androgen receptor in the treatment of male breast cancer.

Published

Journal Article (Review)

Male breast cancer (BC) is relatively rare, making up less than 1% of all breast cancer cases in the United States. Treatment guidelines for male BC are derived from studies on the treatment of female BC, and are based molecular and clinical characteristics, such as hormone receptor positivity. For female estrogen receptor positive (ER+) breast cancers, the standard of care includes three classes of endocrine therapies: selective estrogen receptor modulators, aromatase inhibitors, and pure anti-estrogens. In contrast to female ER+ breast cancers, there is less known about the optimal treatment for male ER+ BC. Furthermore, in contrast to ER, less is known about the role of the androgen receptor (AR) in male and female BC. We report here the treatment of a 28-year-old man with metastatic AR+, ER+ breast cancer otherwise refractory to chemotherapy, who has had a durable clinical response to hormonal suppression with the combination of aromatase inhibition (Letrozole) in conjunction with a GnRH agonist (Leuprolide).

Full Text

Duke Authors

Cited Authors

  • Zhu, J; Davis, CT; Silberman, S; Spector, N; Zhang, T

Published Date

  • February 2016

Published In

Volume / Issue

  • 98 /

Start / End Page

  • 358 - 363

PubMed ID

  • 26669267

Pubmed Central ID

  • 26669267

Electronic International Standard Serial Number (EISSN)

  • 1879-0461

International Standard Serial Number (ISSN)

  • 1040-8428

Digital Object Identifier (DOI)

  • 10.1016/j.critrevonc.2015.11.013

Language

  • eng